| ICD9            = {{ICD9|753.1}}
| ICDO            =
| OMIM            = 601313
| OMIM_mult       = {{OMIM|173910||none}}
| MedlinePlus     = 000502
| eMedicineSubj   = radio
| eMedicineTopic  = 68
| DiseasesDB      = 10262
| MeshID          = D016891
| Orphanet        = 730
| risks           =
| diagnosis       =
| differential    =
| prevention      =
| treatment       =
| medication      =
| prognosis       =
| frequency       =
| deaths          =
}}
'''Autosomna dominantna policistna bubrežna bolest''' ('''ADPKD''') je najrasprostranjenija, potencijalno smrtonosna, [[monogensko nasljeđivanje|monogenski ljudski poremećaj]].<ref name="TP-150518-E20">{{cite journal |vauthors=Torres VE, Harris PC, Pirson Y |title= Autosomal dominant polycystic kidney disease |journal= Lancet |volume= 369 |issue= 9569 |pages= 1287–1301 |year= 2007 |pmid= 17434405 |doi= 10.1016/S0140-6736(07)60601-1 |s2cid= 1700992 }}</ref> Povezana je s velikom međuporodičnom i unutarporodičnom varijabilnošću, što se u velikoj mjeri može objasniti  genetičkom heterogenošću i [[modifikator gena|modifikacijom djelovanja gena]]. Također je najčešća od nasljednih [[cistaste bolesti bubrega|cistastih bolesti bubrega]] – grupe poremećaja sa povezanom, ali različitom patogenezom, karakteriziranom razvojem [[bubrežna cista|bubrežnim cistama]] i različitim vanbubrežnim manifestacijama, koje u slučaju ADPKD uključuju ciste u drugim organima, kao što su [[jetra]], [[sjemeni mjehurić]], [[gušterača]] i [[arahnoidna membrana]], kao i druge abnormalnosti, poput intrakranijalnih [[aneurizma|aneurizmi]] i [[dolihoektazijaza]], [[korijen aorte]] dilatacija i aneurizme, prolaps [[mitralni zalistak|mitralnog zaliska]] i [[hernija|hernije]] [[trbušni zid|trbušnog zida]].<ref name="TP-150518-E20" /><ref name="Dalgaard_1957">{{cite journal |author=Dalgaard OZ |title=Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families |journal=Acta Med. Scand. Suppl. |volume=328 |pages=1–255 |year=1957 |pmid=13469269 }}</ref><ref name=torres>{{cite journal | title=Autosomal dominant polycystic kidney disease: the last 3 years | first1=Vicente| last1=Torres | last2=Harris | first2=Peter C | journal=Kidney International | date=20. 5. 2009 | volume= 76 | pages=149–168| pmid = 19455193  | pmc=2812475 | doi = 10.1038/ki.2009.128 | issue=2}}</ref> Preko 50% pacijenata sa ADPKD-om na kraju razvije [[bubrežna insuficijencija|završni stadij bubrežne bolesti]] i treba [[dijaliza|dijalisu]] ili [[transplantacija bubrega|transblantaciju bubrega]].<ref name="TP-150518-E20" /><ref name="grantham">{{cite journal |author= Grantham JJ |title= Clinical practice. Autosomal dominant polycystic kidney disease |journal= N. Engl. J. Med. |volume= 359 |issue= 14 |pages= 1477–1485 |year= 2008 |pmid= 18832246 |doi= 10.1056/NEJMcp0804458 }}; Reprinted in {{cite journal |pmc= 2843931 | pmid=20009161 | volume=14 | issue=4 | title=Autosomal dominant polycystic kidney disease and transplantation | year=2009 |vauthors=Niemczyk M, Niemczyk S, Paczek L| journal=Ann Transplant | pages=86–90}}</ref> Procjenjuje se da ADPKD utiče na najmanje jednu na svakih 1.000 osoba širom svijeta, čineći ovu bolest najčešćim nasljednim poremećajem bubrega s dijagnosticiranom prevalencijom 1:2000 i incidencijom 1:3000–1: 8000 u globalnim razmjerima.<ref name="TP-150514-001">{{cite journal |vauthors=Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S |title= The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial |journal= Clin Exp Nephrol |volume=  19|issue= 5|pages= 867–877|year=2015 |pmid= 25663351|doi= 10.1007/s10157-015-1086-2|s2cid= 12124902 }}</ref><ref name="TP-150514-002">{{cite journal |vauthors=Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, Kurokawa K |title= Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan |journal= Nephron |volume= 80 |issue= 4|pages= 421–427 |year= 1998 |pmid= 9832641|doi= 10.1159/000045214|s2cid= 22124996 }}</ref><ref name="TP-150514-003">{{cite journal |vauthors=Levy M, Feingold J |title= Estimating prevalence in single-gene kidney diseases progressing to renal failure |journal= Kidney Int. |volume= 58 |issue= 3|pages= 925–943 |year= 2000 |pmid= 10972657|doi= 10.1046/j.1523-1755.2000.00250.x}}</ref><ref name="TP-150514-004">{{cite journal |vauthors=Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS |title= Tolvaptan in patients with autosomal dominant polycystic kidney disease |journal= N. Engl. J. Med. |volume= 367 |issue= 25|pages= 2407–2418 |year= 2012 |pmid= 23121377|doi= 10.1056/NEJMoa1205511|pmc= 3760207}}</ref><ref name="TP-150514-005">{{cite journal |vauthors=Cornec-Le Gall E, Le Meur Y |title= Autosomal dominant polycystic kidney disease: is the treatment for tomorrow? |journal= Nephrol. Ther. |volume= 10 |issue= 6|pages= 433–440 |year= 2014 |pmid= 25086476|doi= 10.1016/j.nephro.2014.03.003}}</ref>